Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.

导出 OA

翻译打印收藏纠错

作者： Albert,Muñoz-Vendrell ^[1] ; Pablo,Arroyo-Pereiro ^[2] ; Isabel,León ^[1] ; Laura,Bau ^[1] ; Elisabet,Matas ^[1] ; Antonio,Martínez-Yélamos ^[1] ; Sergio,Martínez-Yélamos ^[1] ; Lucía,Romero-Pinel ^[1]

作者单位： Neurology Department, Multiple Sclerosis Unit, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Carrer de la Feixa Llarga S/N, 08907, Barcelona, Spain. ^[1] Neurology Department, Multiple Sclerosis Unit, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, L'Hospitalet de Llobregat, Carrer de la Feixa Llarga S/N, 08907, Barcelona, Spain. pablo.arroyo@bellvitgehospital.cat. ^[2]

关键词 JC virus Natalizumab Natural experiment Ocrelizumab Pseudo-randomization Switching

主题词人类(Humans);多发性硬化, 复发缓解性(Multiple Sclerosis, Relapsing-Remitting);JC病毒(JC Virus);危险性评估(Risk Assessment);免疫因子类(Immunologic Factors);脑白质病, 进行性多灶性(Leukoencephalopathy, Progressive Multifocal)

DOI 10.1007/s00415-023-11645-x

PMID 36913038

发布时间 2023-05-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交